Müller HL, Tauber M, Lawson EA et al (2022) Hypothalamic syndrome. Nat Rev Dis Primers 8(1):24

Article  PubMed  Google Scholar 

Roth CL (2011) Hypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits. Front Endocrinol 2:49

Article  Google Scholar 

Müller HL (2020) Management of hypothalamic obesity. Endocrinol Metab Clin North Am 49(3):533–552

Article  PubMed  Google Scholar 

Karavitaki N, Cudlip S, Adams CBT, Wass JAH, Craniopharyngiomas (2006) Endocr Rev 27(4):371–397

Article  PubMed  Google Scholar 

Gatta-Cherifi B, Mohammedi K, Cariou T et al (2024) Impact of exenatide on weight loss and eating behaviour in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial. Eur J Endocrinol Published Online March 7. https://doi.org/10.1093/ejendo/lvae024

Silver HJ, Olson D, Mayfield D et al (2023) Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: a randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab 25(8):2340–2350

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989–1002

Article  CAS  PubMed  Google Scholar 

Drucker DJ (2022) GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351

Article  CAS  PubMed  Google Scholar 

Perez FA, Elfers C, Yanovski JA, Shoemaker AH, Abuzzahab MJ, Roth CL (2021) MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity. Diabetes Obes Metab 23(7):1532–1541

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roth CL, Perez FA, Whitlock KB et al (2021) A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes Obes Metab 23(2):363–373

Article  CAS  PubMed  Google Scholar 

Zoicas F, Droste M, Mayr B, Buchfelder M, Schöfl C (2013) GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol 168(5):699–706

Article  CAS  PubMed  Google Scholar 

Roth CL, McCormack SE (2024) Acquired hypothalamic obesity: a clinical overview and update. Diabetes Obes Metab 26(Suppl 2):34–45

Article  PubMed  Google Scholar 

Sciacovelli C, Moschione G, Garelli S, Pagotto U (2023) Semaglutide for treating obesity Induced by Craniopharyngioma Resection: a successful case study. JCEM Case Rep 1(4):luad074

Article  PubMed  PubMed Central  Google Scholar 

Müller TD, Blüher M, Tschöp MH, DiMarchi RD (2022) Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 21(3):201–223

Article  PubMed  Google Scholar 

Gabery S, Salinas CG, Paulsen SJ et al (2020) Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5(6). https://doi.org/10.1172/jci.insight.133429

Karlsson J, Persson LO, Sjöström L, Sullivan M (2000) Psychometric properties and factor structure of the three-factor eating questionnaire (TFEQ) in obese men and women. Results from the Swedish obese subjects (SOS) study. Int J Obes Relat Metab Disord 24(12):1715–1725

Article  CAS  PubMed  Google Scholar 

de Lauzon B, Romon M, Deschamps V et al (2004) The three-factor eating Questionnaire-R18 is able to distinguish among different eating patterns in a general population. J Nutr 134(9):2372–2380

Article  PubMed  Google Scholar 

Cappelleri JC, Bushmakin AG, Gerber RA et al (2009) Psychometric analysis of the three-factor eating Questionnaire-R21: results from a large diverse sample of obese and non-obese participants. Int J Obes 33(6):611–620

Article  CAS  Google Scholar 

Mostafavi SA, Akhondzadeh S, Mohammadi MR et al (2017) The reliability and validity of the Persian Version of three-factor eating Questionnaire-R18 (TFEQ-R18) in overweight and obese females. Iran J Psychiatry 12(2):100–108

PubMed  PubMed Central  Google Scholar 

Anglé S, Engblom J, Eriksson T et al (2009) Three factor eating questionnaire-R18 as a measure of cognitive restraint, uncontrolled eating and emotional eating in a sample of young Finnish females. Int J Behav Nutr Phys Act 6:41

Article  PubMed  PubMed Central  Google Scholar 

Ng VWW, Gerard G, Koh JJK, Loke KY, Lee YS, Ng NBH (2024) The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review. Clin Obes Published Online January 25:e12642

Google Scholar 

Lomenick JP, Buchowski MS, Shoemaker AH (2016) A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity. Obesity 24(6):1222–1225

Article  CAS  PubMed  Google Scholar 

Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C (2024) A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. Published Online April 18:1–9

Google Scholar 

Bergmann NC, Davies MJ, Lingvay I, Knop FK (2023) Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab 25(1):18–35

Article  CAS  PubMed  Google Scholar 

Kim JH, Choi JH (2013) Pathophysiology and clinical characteristics of hypothalamic obesity in children and adolescents. Ann Pediatr Endocrinol Metab 18(4):161–167

Article  PubMed  PubMed Central  Google Scholar 

Holmer H, Pozarek G, Wirfält E et al (2010) Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma. J Clin Endocrinol Metab 95(12):5395–5402

Article  CAS  PubMed  Google Scholar 

James BL, Loken E, Roe LS, Rolls BJ (2017) The weight-related eating questionnaire offers a concise alternative to the three-factor eating questionnaire for measuring eating behaviours related to weight loss. Appetite 116:108–114

Article  PubMed  PubMed Central  Google Scholar 

Leon AD, Roemmich J, Casperson S (2019) Responses on the three factor eating Questionnaire Restraint and Disinhibition scales Change after a Controlled Energy-Restricted Diet (P21-002-19). Curr Developments Nutr 3(Suppl 1). https://doi.org/10.1093/cdn/nzz041.P21-002-19

van Schaik J, Begijn DGA, van Iersel L et al (2020) Experiences with Glucagon-Like Peptide-1 receptor agonist in children with acquired hypothalamic obesity. Obes Facts 13(4):361–370

Article  PubMed  PubMed Central  Google Scholar 

Ando T, Haraguchi A, Matsunaga T et al (2014) Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity. Intern Med 53(16):1791–1795

Article  PubMed  Google Scholar 

Botero Suarez CS, Broutin D, Yau H (2023) FRI064 the role of GLP-1 receptor agonists in the treatment of Pituitary and Hypothalamic Tumor Induced obesity. J Endocr Soc 7(Supplement1). https://doi.org/10.1210/jendso/bvad114.074